The Role of Infliximab in Pediatric Ulcerative Colitis

Benjamin Koslowsky, Dan Turner

Research output: Contribution to journalArticlepeer-review


Infliximab is a chimeric, monoclonal, anti-tumor necrosis factor (anti-TNF) antibody that is effective in the treatment of both adult and pediatric Crohn's disease (CD) [10]. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.
Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalInternational Journal of Clinical Reviews
StatePublished - 2012

Bibliographical note

Copyright - Copyright Remedica Medical Education and Publishing Apr 2012

Last updated - 2020-11-24


  • Medical Sciences
  • Inflammatory bowel disease
  • Drug therapy
  • Studies
  • Biological products
  • TNF inhibitors
  • Lymphoma


Dive into the research topics of 'The Role of Infliximab in Pediatric Ulcerative Colitis'. Together they form a unique fingerprint.

Cite this